Dr Reddy’s Laboratories has launched three products in the US market, namely, Donepezil Hydrochloride tablets (5mg and 10mg strengths), Venlafaxine Hydrochloride Extended Release capsules (37.5mg, 75mg and 150mg strengths) and Letrozole tablets, USP (2.5mg).
The Food & Drug Administration (FDA) approved Dr Reddy’s ANDA for Donepezil HCl tablets, a bioequivalent generic version of ARICEPT tablets, as on May 31, 2011. Both strengths of Dr Reddy’s Donepezil Hydrochloride tablets are available in 30, 90 and 500 count bottles.
Meanwhile, the FDA approved company’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules, a bioequivalent generic version of EFFEXOR XR Extended Release capsules, as on May 05, 2011. All three strengths of Dr Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles. Lastly, the FDA approved Dr Reddy’s ANDA for Letrozole tablets, USP, a bioequivalent generic version of FEMARA, on June 3, 2011. The company’s Letrozole tablets, USP are available in 30 count bottles.
According to IMS Health the ARICEPT brand and Donepezil Hydrochloride tablets generic version had total combined U.S. sales of approximately $2.3 billion for the twelve months ending March 31, 2011. The EFFEXOR XR brand and Venlafaxine Extended Release Capsules generic had total combined U.S. sales of approximately $2.3billion during the same period. Moreover, the FEMARA brand as reported had U.S. sales of approximately $702 Million for the twelve months ending March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
